摘要
目的 探讨放射治疗后配合DF方案化疗对食管癌的治疗价值。方法 将 192例食管癌患者随机分为 2个组行前瞻性临床研究。一组 96例行放射治疗后配合DF方案化疗 (综合组 ) ,另一组 96例行单纯放射治疗 (单放组 )。放射治疗采用 6MVX射线常规照射 ,DT6 0～ 70Gy ;化疗在放射治疗后 1个月内按计划每 3周行 1个周期。 2个组均随访 3年。结果 综合组与单放组 1,2 ,3年生存率分别为 6 1.5 % ,44 .8% ,34 .4%和 45 .8% ,31.3% ,18.8%。综合组 1,2 ,3年生存率明显高于单放组 (P <0 .0 5 ) ,且无严重毒副反应发生。 2个组局控率差异无显著意义 (P >0 .0 5 ) ,但远地转移率综合组明显低于单放组 (P <0 .0 5 )。放射治疗后晚期食管损伤 ,综合组显著高于单放组 (P <0 .0 1)。结论 放射治疗食管癌后配合DF方案化疗是疗效较好。
Objective To study the therapeutic effect of chemotherapy with DF regimen after radiotherapy for esophageal carcinoma. Methods From August 1994 to June 1996, a prospective randomized trial on chemotherapy with DF regimen after radiotherapy for esophageal carcinoma was carried out in 192 patients. Patients younger than 70 years, at least on semiliquid diet, were randomized into combined group (R+C , 96 patients) or radiotherapy alone group (R, 96 patients). 6MV photon was used for all patients, using 3 fields to deliver 60～70?Gy. Chemotherapy was given every 3 weeks for 4～6 cycles after radiotherapy in R+C group. Both groups were followed for 3 years. Results The one, two and three year survival rates were 61.5%(59/96), 44.8%(43/96), 34.4%(33/96) in R+C group and 45.8%(44/96), 31.3%(30/96), 18.8%(18/96) in R group, respectively. The survival rates in R+C group were much better than those in R group(P<0.05). The local control rates, 45.8% (44/96) in R+C group and 52.1% (50/96) in R group, had no difference (P>0.05) . But there was significant difference in distant metastasis between two groups,5.2%(5/96) in R+C group and 16.7%(16/96) in R group. R+C group was much lower than R group (P<0.05). The late injury of esophagus ,34.4%(33/96) in R+C group and 17.7% (17/96) in R group , was much higher in the former than that in the latter(P<0.01). Conclusions Chemotherapy with DF regimen after radiotherapy for esophageal carcinoma has good effect and is worth further studying in clinic.
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2000年第1期20-22,共3页
Chinese Journal of Radiation Oncology
关键词
食管肿瘤
放射疗法
药物疗法
DF方案
Esophageal neoplasms/radiotherapy
Esophageal neoplasms/drug therapy
Combined modality therapy
